Background.-Migraine is a common yet underdiagnosed and undertreated neurological disease often associated with significant disability. Acute prescription medications are underused, in part because patients discontinue treatment. Rates and reasons for discontinuing acute prescription medications require exploration.
INTRODUCTION
Migraine is a chronic disease with episodic attacks that affects approximately 1 in 7 individuals worldwide. 1 Migraine attacks are characterized by moderate to severe headache pain that is often throbbing and frequently unilateral, and often accompanied by nausea, vomiting, and sensitivity to light, sound, or movement. 2 According to the World Health Organization and the Global Burden of Disease Study (2017), migraine is the second-highest cause of years lived with disability. 1 The primary goals for the acute treatment of migraine attacks include the rapid relief of pain and associated symptoms, restoration of function, minimal recurrence, reducing subsequent resource use, being cost-effective, and minimizing the occurrence of adverse events. 3 Widely used options for the acute pharmacologic treatment of migraine attacks include medications that are not specific for migraine, such as nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and barbiturates, as well as migraine-specific medications, such as triptans and ergots. 4 However, for many individuals, these acute treatments are associated with limited effectiveness, poor tolerability, or contraindications. 5 For example, because of potential complications, NSAIDs should be used with caution in individuals with cardiovascular disease, and avoided in those with ulcers or renal disease, or those taking anticoagulants. 6 Triptans are contraindicated in individuals with cardiovascular disease and use is restricted in patients with multiple cardiovascular risk factors. 7, 8 Furthermore, opioids and barbiturates are not recommended for the acute treatment of migraine attacks because of limited efficacy and the risk of tolerance, dependence, and migraine progression. 9, 10 Acute treatment options for migraine attacks are often poorly optimized for many people and may fail to meet treatment goals. [11] [12] [13] [14] Suboptimal acute treatment of migraine attacks can be associated with an increased likelihood of disability and a substantially increased risk of migraine disease progression. 14, 15 Poorly controlled or uncontrolled attacks may lead to overuse of acute headache medications. Acute medication overuse is associated with greater headache severity and increased pain intensity. 16 Excessive use of medication is also associated with a greater likelihood of progression from episodic migraine to chronic migraine. 17, 18 In the prior American Migraine Prevalence and Prevention (AMPP) study, fewer than 1 in 5 people with migraine reported the use of migraine-specific prescription medications for the acute treatment of migraine. 4 Many individuals with migraine report dissatisfaction with their current acute treatment, with a high number of individuals reporting discontinuing or switching to alternative treatment options. [19] [20] [21] [22] Lack of efficacy and/or side effects often lead to discontinuation of acute treatment. Understanding the primary reasons for treatment dissatisfaction and subsequent discontinuation of acute treatment of migraine attacks could help to identify unmet treatment needs. Identifying and addressing these needs should lead to improved treatment and better outcomes.
The goals of this paper are to quantify rates of acute treatment discontinuation, to characterize people with migraine who discontinue acute treatment use, to understand the reasons for discontinuation, and to assess the burden of migraine among those who discontinue acute prescription medications for migraine. The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study provides an ideal setting for addressing these issues.
METHODS

Study
Design.-The complete CaMEO study design and baseline data have been previously reported. 23 Although a power analysis was not implemented for the initial data collection effort, the sampling plan was intended to provide data on sufficient numbers of high-frequency and chronic migraine respondents to characterize this subset of the population. The study was approved by the institutional review board of the Albert Einstein College of Medicine, which waived written informed consent for study volunteers.
The study consisted of a series of Internet-based longitudinal survey modules issued at 3-month intervals and several cross-sectional modules administered once each over the course of a year between September 2012 and November 2013. Migraine respondents were identified based on modified International Classification of Headache Disorders, 3rd edition (ICHD-3) migraine criteria, as assessed by the American Migraine Study (AMS)/AMPP study diagnostic module. 24 Invitations to participate were sent via e-mail to 489,537 members of an Internet research panel using quota sampling to produce a sample that represented the US population, yielding 80,783 respondents; 58,418 of the returns were usable (ie, provided data sufficient to determine migraine status), and 16,789 of these met study inclusion criteria. The present cross-sectional, descriptive analysis used answers from the CaMEO baseline assessment that included sociodemographic and headache features (screening module), burden measures (core module), and prescription acute medication use (barriers to care module). Baseline survey data were obtained between September 2012 and October 2012. A subsequent survey was administered in October 2012 and November 2012 to assess migraine endophenotypes and allodynia. The authors had full access to all study data.
Study Population and Assessments.-For this analysis, only respondents who had discontinued the use of acute prescription medications for migraine were evaluated. To be included in the analysis, respondents must have selected that they "had ever used" a "prescription pain medication that you take when you get a headache (or feel one coming on)" in response to the question, "Which of the following types of headache treatments have you ever used to treat or manage your headache pain?" All available responses are shown in Supplementary Table S1. To qualify as a "discontinued user," respondents had to indicate that they had used prescription pain medication in the past but were "not currently using" "prescription pain medication that you take when you get a headache (or feel one coming on)." The analysis population was further refined to eliminate individuals with contradictory responses. Respondents who indicated that they had discontinued acute prescription medication for migraine were presented with a list of potential reasons ( Supplementary  Table S2 ). Focus group discussions among persons with migraine and expert clinician input guided development of the initial "reasons" item set. Cognitive debriefing before fielding the survey eliminated redundant items and confirmed readability and interpretation. For the analysis, similar items from the list were grouped into 4 domains: lack of efficacy, safety/tolerability concerns, switched from prescription medication, and financial concerns. The following items were reported separately: switched to preventive medication, headaches improved, and doctor's orders.
Additional patient-reported outcome measures included the Migraine Disability Assessment (MIDAS), Patient Health Questionnaire 9-item depression screener (PHQ-9), and Generalized Anxiety Disorder 7-item screener (GAD-7). The MIDAS questionnaire comprises 5 headache-related disability questions; the score is derived by summing the number of lost days recorded for each question. 25 MIDAS scores are descriptively analyzed based on severity category: grade I (minimal or infrequent disability, score 0-5), grade II (mild or infrequent disability, score 6-10), grade III (moderate disability, score [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , and grade IV (severe disability, score ≥21). The ability to function with respect to headache was also assessed in the Barriers to Care module with a single question ("How are you usually affected by your headaches?"). The PHQ-9 is composed of 9-items pertaining to depression. 26 Each item is rated on a 4-point scale, ranging from 0 (never) to 3 (nearly every day) for the preceding 2 weeks; overall scores range from 0 to 27. PHQ-9 scores are descriptively analyzed based on severity category, with the scores of 5-9, 10-14, 15-19, and 20-27, corresponding to mild, moderate, moderately severe, and severe depression, respectively. The GAD-7 consists of 7-items that describe symptoms of generalized anxiety disorder for the preceding 2 weeks that are rated on a 4-point scale that ranges from 0 (not at all) to 3 (nearly every day), for a total score range of 0 to 21. 27 GAD-7 scores are descriptively analyzed based on severity category, with scores of 5-9, 10-14, and 15-21 corresponding to mild, moderate, and severe anxiety, respectively. The presence of allodynia was assessed with the 12-item Allodynia Symptom Checklist (ASC-12). Responses for this scale were obtained from the endophenotypes module that was administered during a subsequent assessment. The ASC-12 includes questions about the frequency of allodynia symptoms associated with migraine attacks; items are scored on a 3-point scale, ranging from 0 (never, rarely, or does not apply to me) to 2 (half of the time or more), for a total score that ranges from 0 to 24. 28 The ASC-12 is descriptively analyzed based on severity category: none (score 0-2), mild (score 3-5), moderate (score 6-8), and severe (9 or more). Monthly headache day frequency was assessed in the screening and core modules, and the latter also encompassed an accounting of headache treatments used within the previous 30 days.
Statistical Analyses.-Sociodemographic features, headache characteristics, and reasons for discontinuation of acute prescription medication were summarized descriptively as the percentage of respondents endorsing each variable. Study population age was characterized with mean and standard deviation. Monthly headache days within subgroups were summarized by median and 25th/75th per centile. Some respondents were missing data for sociodemographics and headache characteristics and are identified in the respective tables. MIDAS, PHQ-9, and GAD-7 scores are descriptively analyzed; the number of respon dents meeting criteria for each severity category is reported. No formal statistical testing for differences between groups was performed. All analyses were conducted with IBM SPSS Statistics, version 20.0 (IBM, Armonk, NY, USA).
RESULTS
CaMEO Analysis
Sample.-In total, 13,624 total respondents were included in these analyses. Only 4840 (35.5%) respondents reported ever using acute prescription medication for migraine, and 1719 (35.5%) of that subgroup reported discontinuing the use of acute prescription medication for migraine. Among those who discontinued treatment, the mean (SD) age was 42.1 (14.0) years, and 78.4% were female. Full demographics stratified by time since discontinuation are shown in Table 1 . Nearly twothirds (65.6%) of those who discontinued treatment had a body mass index in the category of overweight or obese. While the majority of respondents who discontinued treatment reported active health insurance coverage (84.6%), most were not currently consulting with a healthcare professional about their headaches (87.5%). Demographic characteristics across the time since discontinuation groups were generally similar, with the highest mean age in the >12-month subgroup (43.6 years).
Respondents' headache characteristics stratified by the time since discontinuation are shown in Table 2 . Nearly 50% of those who discontinued had allodynia, and 37.6% reported 5 or more headache days per month, with a median (25th/75th percentile) of 3.3 (1.3, 6.7) days. Two-thirds (67.5%) of discontinued users reported receiving a migraine (or chronic migraine) diagnosis from a doctor or other health professional in the past. Those who had discontinued treatment within the previous year were more likely to have experienced at least 15 headache days per month than those who discontinued 12 months before.
Migraine Disability, Depression, and Anxiety.-Only 19.1% of respondents who discontinued treatment reported being able to work or function normally with headache; 59.5% reported their working ability or activity was impaired to some degree; 10.8% reported their working ability or activity was severely impaired, but required no bed rest; and 10.6% reported that bed rest was required. Assessment of migraine-related disability as measured by MIDAS score showed 41.7% of respondents who discontinued treatment scored within the moderate to severe disability range at baseline (Fig. 1) . Furthermore, approximately one-third of respondents who discontinued treatment exhibited moderate to severe depression (33.0%) and/or moderate to severe anxiety (30.0%), as assessed by the PHQ-9 and GAD-7, respectively. medication discontinuation was the decision to switch away from prescription medication (45.5%) to overthe-counter or alternative treatment options, followed by concerns about lack of efficacy (28.2%) and safety/ tolerability (24.9%) ( Table 3) . Additionally, 21.3% of respondents who discontinued treatment reported doing so because their headaches had improved and 19.4% reported financial concerns. Reasons for discontinuing treatment were further evaluated to assess the overlap of efficacy and concerns about safety and tolerability in this subpopulation. Among those who reported discontinuing medication due to a lack of efficacy, 33.1% (160/484) also reported safety and tolerability concerns. Among those who reported safety and tolerability concerns, 37.4% (160/428) of respondents also reported a lack of efficacy as a reason contributing to treatment discontinuation.
Reasons Reported as Contributing to Acute Prescription Medication Discontinuation.-The most common reason associated with acute prescription
The degree of migraine-related disability was lowest in those whose headaches improved and those who reportedly switched away from prescription medications (Fig. 2) . The highest rates of severe migraine-related disability were among those who discontinued acute treatment because they started preventive treatment (41.9%), discontinued due to doctor's instruction (37.9%), or reported financial concerns (33.9%). Among those respondents who discontinued treatment due to lack of efficacy and/or safety/tolerability concerns (n = 752), higher rates of moderate or severe disability were found among those who discontinued for both efficacy and safety/tolerability reasons (64.4%) than because of efficacy or safety/tolerability alone (Fig. 3) .
DISCUSSION
In this analysis of CaMEO study respondents, 35.5% of those who had ever tried an acute prescription medication for migraine discontinued use. A full characterization of respondents who reported never using or continued use of acute prescription medications for migraine has been presented separately. 29 Common reasons for discontinuing treatment included switching to over-the-counter treatments, lack of efficacy, and concerns about medication safety and tolerability. Reasons related to financial concerns were also prevalent, with 11.0% of respondents indicating that they discontinued due to lack of health insurance and 12.6% endorsing the idea that out of pocket costs were too high or medication was inadequately covered by insurance.
Among discontinued users, many (37%) reported still having more than 4 headache days per month. Additionally, more than 40% of respondents who discontinued acute prescription medication for migraine experienced moderate to severe migraine disability on the MIDAS questionnaire, 33% reported moderate to severe depression, and 30% reported moderate to severe anxiety. These data indicate a substantial unmet need among those who discontinue acute prescription medications. When evaluating the relationship between migraine disability and reasons for discontinuation, the highest levels of disability were found in respondents who discontinued because of concerns regarding both efficacy and tolerability, indicating a potential need for medications with improved efficacy and tolerability profiles. Notably, 87.5% of the overall respondents were not currently consulting with a healthcare provider, which likely limited their treatment options.
These results parallel those from other studies that have identified efficacy and safety concerns as influencing a patient's decision to discontinue his or her acute medication. 11, 13, [30] [31] [32] [33] In an analysis of the AMPP study data, investigators found that the most commonly reported reasons for discontinuation of triptans and opioids were related to efficacy and safety. 11 Specific reasons included failure to relieve pain (29.6%), recurrence of pain after initial relief (24.1%), concern about medication affecting stomach (20.8%), concern about side effects in general (18.8%), and medication stopped working (17.5%). In a multicenter cross-sectional survey of US headache clinics, individuals with migraine reported a lack of efficacy (44%) and concerns with side effects (29%) as the most common reasons for discontinuation of triptan use. 13 Additionally, those who discontinued triptans in this study had higher depression and higher disability scores, which is consistent with our data showing a sizable headache-related burden in the form of depression and disability among respondents who discontinued medication. In agreement with these results, Cady et al found that satisfaction with treatment and belief in medication were the most significant predictors of continued and sustained triptan use. 31 In an evaluation of patients who switched between triptans, the investigators found that "incomplete or no relief " and inadequate "time to relief " were the most common reasons contributing to the decision to switch. 30 Results from the Migraine in America Symptoms and Treatment (MAST) Study also included high rates of discontinuation analyzed by route of drug administration, including injectable triptans (81.5%), nasal sprays (66.5%), and oral triptans (55.2%). 33 A reported lack of efficacy and concerns over side effects were the most common reasons for discontinuing triptans among these respondents. For oral triptans, the most commonly reported side effects associated with treatment discontinuation were dizziness (37.4%) and nausea (30.7%).
The limitations of the CaMEO Study have been discussed previously. 23 All data were self-reported and not confirmed by medical claims or medical records, and were subject to the recall bias that is inherent with any survey-based methodology. Reasons for discontinuing acute prescription medication for migraine were self-reported and, for some respondents, based on action taken many months before this assessment. Additionally, different rates of treatment dissatisfaction and discontinuation between acute medications have been reported. 11 As our analysis was not subcategorized by acute treatment type, our results do not address differences across medications. Strengths of the CaMEO study include the fact that it is a large, nationwide, diverse sample of people with migraine, and relies on validated assessment tools where possible. Non-validated measures were derived from migraine patient interviews and expert clinician guidance.
CONCLUSIONS
These results further confirm a high level of disability and unmet treatment need among those with migraine who discontinue acute prescription medication for migraine. Switching away from prescription treatments, a lack of efficacy, and concerns over safety and tolerability were among the most commonly reported reasons contributing to discontinuation. Addressing efficacy and safety concerns commonly associated with these medications may help to improve treatment adherence, improve outcomes for patients, and mitigate the societal burden of migraine.
